Could geriatric characteristics explain the under-prescription of anticoagulation therapy for older patients admitted with atrial fibrillation?: A retrospective observational study

Drugs and Aging

Volumn 27, Issue 10, 2010, Pages 807-813

  De Breucker, Sandra ^a   Herzog, Gertraud ^a   Pepersack, Thierry ^a  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

Anticoagulants, therapeutic use; Atrial fibrillation; Elderly; Vitamin K antagonists, therapeutic use.

Indexed keywords

ANTIVITAMIN K;

AGED; ANTICOAGULANT THERAPY; ARTICLE; COGNITIVE DEFECT; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DATA ANALYSIS; DEPRESSION; DIABETES MELLITUS; FALLING; FEMALE; FRAIL ELDERLY; FUNCTIONAL ASSESSMENT; FUNCTIONAL DISEASE; GERIATRIC ASSESSMENT; GERIATRICS; HEART ATRIUM FIBRILLATION; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; HYPERTENSION; INCONTINENCE; MAJOR CLINICAL STUDY; MALE; MALNUTRITION; MEDICAL RECORD REVIEW; OBSERVATIONAL STUDY; PRESCRIPTION; PRIORITY JOURNAL; QUESTIONNAIRE; RETROSPECTIVE STUDY; RISK; STROKE; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ANTIFIBRINOLYTIC AGENTS; ATRIAL FIBRILLATION; DRUG UTILIZATION; FEMALE; GERIATRIC ASSESSMENT; HOSPITALIZATION; HUMANS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; THROMBOEMBOLISM; VITAMIN K; VITAMINS;

EID: 77957743599     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.2165/11537900-000000000-00000     Document Type: Article

References (55)

1. Gallagher AM, Rietbrock S, Plumb J, et al. Initiation and persistence of warfarin or aspirin in patients with chronic atrial fibrillation in general practice: do the appropriate patients receive stroke prophylaxis? J Thromb Haemost 2008 Sep; 6 (9): 1500-6
2. Morgan CL, McEwan P, Tukiendorf A, et al. Warfarin treatment in patients with atrial fibrillation: observing outcomes associated with varying levels of INR control. Thrombosis Res 2009 May; 124 (1): 37-41
3. Thomson R, Eccles M, Wood R, et al. A cautionary note on data sources for evidence-based clinical decisions: warfarin and stroke prevention. Med Decis Making 2007 Jul-Aug; 27(4): 438-47
4. Hart RG, Benavente O, McBride R, et al. Antithrombotic therapy to prevent stroke in patients with atrial fibrilla-tion: ametaanalysis. Ann Intern Med 1999 Oct 5; 131 (7): 492-501
5. Albers GW, Bittar N, Young L, et al. Clinical characteristics and management of acute stroke in patients with atrial fi-brillation admitted to US university hospitals. Neurology 1997 Jun; 48 (6): 1598-604
6. Antani MR, Beyth RJ, Covinsky KE, et al. Failure to prescribe warfarin to patients with nonrheumatic atrial fibrilla-tion. J Gen Intern Med 1996 Dec; 11 (12): 713-20
7. Beyth RJ, Antani MR, Covinsky KE, et al. Why isn't warfarin prescribed to patients with nonrheumatic atrial fibril-lation? J Gen Intern Med 1996 Dec; 11 (12): 721-8
8. Bath PM, Prasad A, Brown MM, et al. Survey of use of anticoagulation in patients with atrial fibrillation. BMJ 1993 Oct 23; 307 (6911): 1045
9. Brass LM, Krumholz HM, Scinto JM, et al. Warfarin use among patients with atrial fibrillation. Stroke 1997 Dec; 28(12): 2382-9
10. Gurwitz JH, Monette J, Rochon PA, et al. Atrial fibrillation and stroke prevention with warfarin in the long-term care setting. Arch Intern Med 1997 May 12; 157 (9): 978-84
11. Monette J, Gurwitz JH, Rochon PA, et al. Physician attitudes concerning warfarin for stroke prevention in atrial fibrillation: results of a survey of long-term care practi-tioners. J Am Geriatr Soc 1997 Sep; 45 (9): 1060-5
12. Munschauer FE, Priore RL, Hens M, et al. Thromboembolism prophylaxis in chronic atrial fibrillation: practice patterns in community and tertiary-care hospitals. Stroke 1997 Jan; 28 (1): 72-6
13. Fang MC, Stafford RS, Ruskin JN, et al. National trends in antiarrhythmic and antithrombotic medication use in atrial fibrillation. Arch Intern Med 2004 Jan 12; 164 (1): 55-60
14. Cohen N, Almoznino-Sarafian D, Alon I, et al. Warfarin for stroke prevention still underused in atrial fibrillation: pat-terns ofomission. Stroke 2000 Jun; 31 (6): 1217-22
15. Majeed A, Moser K, Carroll K. Trends in the prevalence and management ofatrial fibrillation in general practice in England and Wales, 1994-1998: analysis of data from the general practice research database. Heart 2001 Sep; 86 (3): 284-8
16. Stewart S, Murphy NF, Walker A, et al. Cost of an emerging epidemic: an economic analysis of atrial fibrillation in the UK. Heart 2004 Mar; 90 (3): 286-92
17. Gottlieb LK, Salem-Schatz S. Anticoagulation in atrial fibrillation: does efficacy in clinical trials translate into effectiveness in practice? Arch Intern Med 1994 Sep 12; 154 (17): 1945-53
18. Brodsky MA, Chun JG, Podrid PJ, et al. Regional attitudes of generalists, specialists, and subspecialists about manage-ment ofatrial fibrillation. Arch Intern Med 1996 Dec 9-23; 156 (22): 2553-62
19. Brodsky MA, Podrid PJ, Chun JG. Should physicians participate in affirming the best approach to atrial fibrillation management? Am J Cardiol 1996 Nov 15; 78 (10): 1152-3
20. Chang HJ, Bell JR, Deroo DB, et al. Physician variation in anticoagulating patients with atrial fibrillation. Dartmouth Primary Care COOP Project. Arch Intern Med 1990 Jan; 150 (1): 83-6
21. Kutner M, Nixon G, Silverstone F. Physicians' attitudes toward oral anticoagulants and antiplatelet agents for stroke prevention in elderly patients with atrial fibrillation. Arch InternMed 1991 Oct; 151 (10): 1950-3
22. Lip GY, Zarifis J, Watson RD, et al. Physician variation in the management ofpatients with atrial fibrillation. Heart 1996 Feb; 75 (2): 200-5
23. McCrory DC, Matchar DB, Samsa G, et al. Physician attitudes about anticoagulation for nonvalvular atrial fibril-lation in the elderly. Arch Intern Med 1995 Feb 13; 155 (3): 277-81
24. Buksinska-Lisik M. BAFTA Study. Comparison of aspirin and warfarin in preventive maintenance of stroke in the oldest persons with atrial fibrillation. Kardiol Pol 2007 Nov; 65 (11): 1399-400
25. Di Pasquale G, Palareti G. The BAFTA study. G Ital Cardiol 2008 Nov; 9 (11): 735-9
26. Diug B, Lowthian J, Evans S. Warfarin versus aspirin for stroke prevention (BAFTA). Lancet 2007 Nov 10; 370 (9599): 1606; author reply: 7
27. Hart RG. Did we really need another comparison ofwarfarin with aspirin? An assessment of the BAFTA trial. Pol Arch Med Wewn 2007 Oct; 117 (10): 443-5
28. Hurley V, Ireson R, Fletcher K, et al. A cross-sectional study of hypertension in an elderly population (75 years and over) with atrial fibrillation: secondary analysis of data from the Birmingham Atrial Fibrillation in the Aged (BAFTA) randomised controlled trial. Int J Cardiol 2007 Apr 25; 117 (2): 152-6
29. Liakishev AA. Warfarin versus aspirin for strokeprevention in an elderly community population with atrial fibrillation. Results of the BAFTA trial. Kardiologia 2008; 48 (2): 68
30. Mant J, Hobbs FD, Fletcher K, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised con-trolled trial. Lancet 2007 Aug 11; 370 (9586): 493-503
31. Mant JW, Richards SH, Hobbs FD, et al. Protocol for Birmingham Atrial Fibrillation Treatment of the Aged study (BAFTA): a randomised controlled trial of warfarin ver-sus aspirin for stroke prevention in the management of atrial fibrillation in an elderly primary care population [ISRCTN89345269]. BMC Cardiovasc Disord 2003 Aug 26; 3: 9-18
32. Mihas C, Alevizos A, Arapaki A, et al. Warfarin versus aspirin for stroke prevention (BAFTA). Lancet 2007 Nov 10; 370 (9599): 1606; author reply: 7
33. Sudlow C, Warlow C. First-ever stroke incidence [letter]. Lancet 1998 Jun 20; 351 (9119): 1892
34. Sudlow M, Thomson R, Thwaites B, et al. Prevalence of atrial fibrillation and eligibility for anticoagulants in the community. Lancet 1998 Oct 10; 352 (9135): 1167-71
35. Kalra L, Perez I, Melbourn A. Risk assessment and anticoagulation for primary stroke prevention in atrial fi-brillation. Stroke 1999 Jun; 30 (6): 1218-22
36. Go AS, Hylek EM, Borowsky LH, et al. Warfarin use among ambulatory patients with nonvalvular atrial fibril-lation: the Anticoagulation and Risk Factors in Atrial Fi-brillation (ATRIA) study. Ann Intern Med 1999 Dec 21; 131 (12): 927-34
37. Bungard TJ, Ghali WA, Teo KK, et al. Why do patients with atrial fibrillation not receive warfarin? Arch Intern Med 2000 Jan 10; 160 (1): 41-6
38. Katz S, Ford AB, Moskowitz RW, et al. Studies ofillness in the aged. The index of ADL: a standardized measure ofbiological and psychosocial function. JAMA 1963 Sep 21; 185: 914-9
39. Lawton MP, Brody EM. Assessment ofolder people: selfmaintaining and instrumental activities of daily living. Gerontologist 1969 Autumn; 9 (3): 179-86
40. Yesavage JA. Geriatric depression scale. Psychopharmacol Bull 1988; 24 (4): 709-11
41. Stratton RJ, Hackston A, Longmore D, et al. Malnutrition in hospital outpatients and inpatients: prevalence, concur-rent validity and ease of use of the 'malnutrition universal screening tool' ('MUST') for adults. Br J Nutr 2004 Nov; 92 (5): 799-808
42. Pepersack T. Minimum geriatric screening tools to detect common geriatric problems. J Nutr Health Aging 2008 May; 12 (5): 348-52
43. Gillespie LD, Gillespie WJ, Cumming R, et al. Interventions for preventing falls in the elderly. Cochrane Database Syst Rev 2000; 2: CD000340
44. Bond AJ, Molnar FJ, Li M, et al. The risk ofhemorrhagic complications in hospital in-patients who fall while receiv-ing antithrombotic therapy. Thromb J 2005 Jan 7; 3 (1): 1
45. Choudhry NK, Soumerai SB, Normand SL, et al. Warfarin prescribing in atrial fibrillation: the impact of physician, patient, and hospital characteristics. Am J Med 2006 Jul; 119 (7): 607-15
46. Connolly SJ. Preventing stroke in atrial fibrillation: why are so many eligible patients not receiving anticoagulant ther-apy? CMAJ 1999 Sep 7; 161 (5): 533-4
47. Man-Son-Hing M, Nichol G, Lau A, et al. Choosing antithrombotic therapy for elderly patients with atrial fibrilla-tion who are at risk for falls. Arch Intern Med 1999 Apr 12; 159 (7): 677-85
48. Howitt A, Armstrong D. Implementing evidence based medicine in general practice: audit and qualitative study of antithrombotic treatment for atrial fibrillation. BMJ 1999 May 15; 318 (7194): 1324-7
49. Protheroe J, Fahey T, Montgomery AA, et al. The impact of patients' preferences on the treatment ofatrial fibrillation: observational study of patient based decision analysis. BMJ 2000 May 20; 320 (7246): 1380-4
50. Pepersack T, Corretge M, Beyer I, et al. Examining the effect of intervention to nutritional problems of hospitalised el-derly: apilotproject. JNutr Health Aging2002; 6 (5): 306-10
51. O'Reilly RA. Interaction of the anticoagulantdrug warfarin and its metabolites with human plasma albumin. J Clin Investig 1969 Jan; 48 (1): 193-202
52. Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med 1998 Aug; 105 (2): 91-9
53. Aspinall SL, DeSanzo BE, Trilli LE, et al. Bleeding risk index in an anticoagulation clinic: assessment by indication and implications for care. J Gen Intern Med 2005 Nov; 20 (11): 1008-13
54. Landefeld CS, Goldman L. Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. Am J Med 1989 Aug; 87 (2): 144-52
55. Davis DA, Thomson MA, Oxman AD, et al. Changing physician performance: a systematic review of the effect of continuing medical education strategies. JAMA 1995 Sep 6; 274 (9): 700-5